Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Shionogi Licenses Ospemifene from QuatRx
March 8, 2010
- Clexane Prevents Postoperative VTE in Japanese: sanofi-aventis
March 8, 2010
- Makers Should Change Their Marketing Method: Prof. Koyama
March 8, 2010
- 16th Edition of JP to See Sweeping Revisions of “General Rules for Preparations”
March 8, 2010
- Recommendation of Switching PPIs to OTC Status Withheld Again
March 8, 2010
- New NHI Pricing System to Provide Big Opportunity for CROs: Mr Nakamura
March 8, 2010
- Korosho to Call on Public Hospitals for Earlier Price Settlement
March 8, 2010
- Oxiconazole Recommended for Approval as OTC Drugs for Vaginal Candidiasis
March 8, 2010
- 2-Week Restriction on Prescription Impedes Use of New Drugs: Mr Umeda of PhRMA
March 8, 2010
- Dr Hotta Calls For Flexible Approach to Applications Based on Data from Public Domain
March 8, 2010
- Legislation of “Specific Nurses”Proposed by Korosho
March 8, 2010
- Daiichi Sankyo to Set Up Japan Company
March 8, 2010
- Abbott Completes Acquisition of Solvay Pharmaceuticals
March 1, 2010
- Nihon Medi-Physics Initiates PI Trial for NMK36
March 1, 2010
- Prospects of Incretin-Related Drugs in Japan: 2(1)
March 1, 2010
- NIMS Develops DES for Vascular Endothelial Formation
March 1, 2010
- Prospects of Incretin-Related Drugs in Japan: 2(2)
March 1, 2010
- CMIC to Support Korean Hospitals in Developing Medical Devices
March 1, 2010
- Korosho Completes Hearings of Makers
March 1, 2010
- Teva-Kowa, Taisho Pharm to Integrate Marketing Divisions
March 1, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…